𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HDAC inhibitors in leukemia: Current status and perspectives

✍ Scribed by Gregory Kouraklis

Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
70 KB
Volume
33
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiarrhythmic agents: Current status an
Antiarrhythmic agents: Current status and perspectives
✍ Péter Mátyus; András Varró; Julius Gy. Papp; Heinrich Wamhoff; Ildikó Varga; Lás 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 573 KB

His research interests are medicinal chemistry of cardiovascular and CNS diseases; as well as synthetic, mechanistic, and computational chemistry of diaza-heterocyclic compounds. He was awarded The Zemplen-Prize from the Hungarian Academy of Sciences.

Wave energy in Europe: current status an
Wave energy in Europe: current status and perspectives
✍ Alain Clément; Pat McCullen; António Falcão; Antonio Fiorentino; Fred Gardner; K 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 687 KB

The progress in wave energy conversion in Europe during the past ten years is reviewed and current activities and initiatives in the wave energy sector at National and Union level are described. Other important activities worldwide are summarized. The technical and econ- \* Corresponding author.

Rice proteomics: Current status and futu
Rice proteomics: Current status and future perspectives
✍ Randeep Rakwal; Ganesh Kumar Agrawal 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB

## Abstract Rice, the first cereal crop genome to be decoded, has attracted the attention of researchers worldwide because of its immense socio‐economic impact on human existence. With the availability of the draft genome sequence of two major types, japonica‐ and indica‐rice, “rice proteomics” has

Inhibitors in hemophilia patients: Curre
Inhibitors in hemophilia patients: Current status and management
✍ Louis Aledort 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 989 KB

## Abstract The development of inhibitor antibodies is a long‐standing, well‐documented complication of coagulation factor replacement therapy and is difficult to treat. Previous estimates of 5–15% of patients developing inhibitors may be low, since newer data suggest a wider range of occurrence. F